ReviewJHEP reports : innovation in hepatology2025
EASL postgraduate course report: Vascular biology in chronic liver disease and clinical management implications.
Review in JHEP reports : innovation in hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From bench to bedside: Molecular mechanisms, diagnostic tools, and therapeutic strategies in liver fibrosis.Liver research (Beijing, China) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews the content of the EASL Congress 2024 postgraduate course on vascular biology in chronic liver disease and its clinical management. It focuses on haemostasis in patients with cirrhosis, vascular liver diseases including porto-sinusoidal vascular disorder and portal vein thrombosis, and portal hypertension and its extrahepatic complications in cirrhosis. Haemostatic changes in cirrhosis coincide with complex shifts between the risks of bleeding and thrombosis, making management decisions challenging. Importantly, laboratory test abnormalities should not be routinely corrected to avoid bleeding. Regarding vascular liver diseases, the term porto-sinusoidal vascular disorder is a recently redefined entity encompassing various overlapping histological patterns (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.